ClinicalTrials.Veeva

Menu

Weight Loss and Breast Cancer

F

Fatih Sultan Mehmet Training and Research Hospital

Status

Not yet enrolling

Conditions

Breast Cancer
Obesity, Morbid

Treatments

Diagnostic Test: mammography

Study type

Observational

Funder types

Other

Identifiers

NCT05654571
ANILERGİNN

Details and patient eligibility

About

Obesity is an important risk factor for postmenopausal breast cancer. A large meta-analysis concluded that obesity is associated with a 20% to 40% increased risk for receptor-positive postmenopausal breast cancer. The International Agency for Research on Cancer working group on obesity and cancer risk drew similar conclusions. Obesity seems to have the opposite effect among premenopausal women, with most studies suggesting that higher BMI is associated with a reduced risk of premenopausal breast cancer.

Determining whether deliberate weight loss is associated with a reduced risk of breast cancer is difficult in part because sustained weight loss is difficult to achieve and few studies have sufficient statistical power to address this question. Bariatric surgery is one of the few weight loss interventions in which significant weight loss is maintained. A limited number of previous studies have suggested a reduced risk of cancer following bariatric surgery. Recently, it showed that bariatric surgery is associated with a lower risk of several types of cancer, including an approximately 40 % reduction in the risk of postmenopausal breast cancer. However, whether bariatric surgery affects breast cancer risk in premenopausal women and whether this association is altered by estrogen receptor (ER) status has not been addressed.

The aim of this study is to examine the relationship between weight loss after laparoscopic sleeve gastrectomy (LSG) and breast cancer.

Full description

In this study, 300 female patients who underwent laparoscopic sleeve gastrectomy due to morbid obesity in Fatih Sultan Mehmet Training and Research Hospital General Surgery Clinic will be included. The number of samples was calculated by performing impact power analysis.

Mamagrophy is recommended for all women over the age of 40 as part of the routine cancer screening program in our country. For this reason, it is assumed that female patients over the age of 40 who have undergone LSG operation have undergone mammography as of 2022. For this reason, the data of these patients will be examined by scanning from the hospital system. Patients who have undergone mammography examination at least 3 years after the LSG operation will be included in the study. The mammograms of the patients who underwent mammography in January 2015 and later will be evaluated. The final diagnosis of breast cancer will be made with the pathology result in patients with suspicious appearance on mamagrophy.

If there is a malignancy detected as a result of the examinations, its size and pathology will be recorded. Patients' age, gender, and total weight loss will be recorded.

In this retrospective study, we aimed to determine the incidence of breast cancer in patients who had undergone LSG surgery and also to determine whether there was a change in breast cancer compared to weight loss.

The patient inclusion criteria are as follows:

  • 40 years and older (age as of 2022, not the age of operation)
  • LSG was applied in our clinic due to morbid obesity.
  • Patients whose mamagrofi images are available in the hospital system

The patient exclusion criteria are as follows:

  • Patients who underwent abdominal surgery again after LSG
  • Patients whose mamagrophy image is not in the system
  • Patients with suspicious findings as a result of mammography and who did not undergo additional imaging or biopsy
  • Patients out of follow-up after the operation

Enrollment

300 estimated patients

Sex

Female

Ages

40+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • 40 years and older (age as of 2022, not the age of operation)
  • LSG was applied in our clinic due to morbid obesity.
  • Patients whose mamagrofi images are available in the hospital system

Exclusion criteria

  • Patients who underwent abdominal surgery again after LSG
  • Patients whose mamagrophy image is not in the system
  • Patients with suspicious findings as a result of mammography and who did not undergo additional imaging or biopsy
  • Patients out of follow-up after the operation

Trial design

300 participants in 2 patient groups

significant weight loss+ breast cancer
Description:
The group that lost significant weight after laparoscopic sleeve gastrectomy and was diagnosed with breast cancer
Treatment:
Diagnostic Test: mammography
regain+breast cancer
Description:
The group who lost significant weight after laparoscopic sleeve gastrectomy and regained it afterwards, or who could not lose weight and were diagnosed with breast cancer
Treatment:
Diagnostic Test: mammography

Trial contacts and locations

1

Loading...

Central trial contact

ANIL ERGİN

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems